These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35752221)

  • 21. Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions.
    Cos S; González A; Martínez-Campa C; Mediavilla MD; Alonso-González C; Sánchez-Barceló EJ
    Cancer Detect Prev; 2006; 30(2):118-28. PubMed ID: 16647824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.
    Kilic U; Yilmaz B; Ugur M; Yüksel A; Reiter RJ; Hermann DM; Kilic E
    J Pineal Res; 2012 Mar; 52(2):228-35. PubMed ID: 21913972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible involvement of the nuclear RZR/ROR-alpha receptor in the antitumor action of melatonin on murine Colon 38 cancer.
    Winczyk K; Pawlikowski M; Guerrero JM; Karasek M
    Tumour Biol; 2002; 23(5):298-302. PubMed ID: 12595746
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular mechanisms of melatonin anticancer effects.
    Hill SM; Frasch T; Xiang S; Yuan L; Duplessis T; Mao L
    Integr Cancer Ther; 2009 Dec; 8(4):337-46. PubMed ID: 20050373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Revealing Melatonin's Mysteries: Receptors, Signaling Pathways, and Therapeutics Applications.
    Kulsoom K; Ali W; Saba Z; Hussain S; Zahra S; Irshad M; Ramzan MS
    Horm Metab Res; 2024 Jun; 56(6):405-418. PubMed ID: 38081221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Melatonin Type 2 Receptor Activation Regulates Blue Light Exposure-Induced Mouse Corneal Epithelial Damage by Modulating Impaired Autophagy and Apoptosis.
    Jin R; Li Y; Jin H; Yoon HS; Choi JS; Kim J; Yoon HJ; Yoon KC
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melatonin.
    Mor M; Plazzi PV; Spadoni G; Tarzia G
    Curr Med Chem; 1999 Jun; 6(6):501-18. PubMed ID: 10213796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photoimmunomodulation and melatonin.
    Haldar C; Ahmad R
    J Photochem Photobiol B; 2010 Feb; 98(2):107-17. PubMed ID: 20080417
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling.
    Wiesenberg I; Missbach M; Carlberg C
    Restor Neurol Neurosci; 1998 Jun; 12(2-3):143-50. PubMed ID: 12671309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic targets of cancer drugs: Modulation by melatonin.
    Moloudizargari M; Moradkhani F; Hekmatirad S; Fallah M; Asghari MH; Reiter RJ
    Life Sci; 2021 Feb; 267():118934. PubMed ID: 33385405
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor.
    Carbajo-Pescador S; García-Palomo A; Martín-Renedo J; Piva M; González-Gallego J; Mauriz JL
    J Pineal Res; 2011 Nov; 51(4):463-71. PubMed ID: 21718361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melatonin: A Potential Antineoplastic Agent in Breast Cancer.
    Samanta S
    J Environ Pathol Toxicol Oncol; 2022; 41(4):55-84. PubMed ID: 36374962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review on Melatonin's Effects in Cancer: Potential Mechanisms.
    Hanikoglu A; Kucuksayan E; Akduman RC; Ozben T
    Anticancer Agents Med Chem; 2018; 18(7):985-992. PubMed ID: 29173185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Melatonin slowed the early biochemical progression of hormone-refractory prostate cancer in a patient whose prostate tumor tissue expressed MT1 receptor subtype.
    Shiu SY; Law IC; Lau KW; Tam PC; Yip AW; Ng WT
    J Pineal Res; 2003 Oct; 35(3):177-82. PubMed ID: 12932201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Melatonin as an apoptosis antagonist.
    Radogna F; Paternoster L; Albertini MC; Accorsi A; Cerella C; D'Alessio M; De Nicola M; Nuccitelli S; Magrini A; Bergamaschi A; Ghibelli L
    Ann N Y Acad Sci; 2006 Dec; 1090():226-33. PubMed ID: 17384266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melatonin in pathogenesis and therapy of cancer.
    Ravindra T; Lakshmi NK; Ahuja YR
    Indian J Med Sci; 2006 Dec; 60(12):523-35. PubMed ID: 17130668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of melatonin and melatonin receptors ligand N-[(4-methoxy-1H-indol-2-yl)methyl]propanamide on murine Colon 38 cancer growth in vitro and in vivo.
    Winczyk K; Pawlikowski M; Lawnicka H; Kunert-Radek J; Spadoni G; Tarzia G; Karasek M
    Neuro Endocrinol Lett; 2002 Apr; 23 Suppl 1():50-4. PubMed ID: 12019352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells.
    Cos S; Fernández R; Güézmes A; Sánchez-Barceló EJ
    Cancer Res; 1998 Oct; 58(19):4383-90. PubMed ID: 9766668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new perspective in Oral health: potential importance and actions of melatonin receptors MT1, MT2, MT3, and RZR/ROR in the oral cavity.
    Cutando A; Aneiros-Fernández J; López-Valverde A; Arias-Santiago S; Aneiros-Cachaza J; Reiter RJ
    Arch Oral Biol; 2011 Oct; 56(10):944-50. PubMed ID: 21459362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis.
    Reiter RJ; Rosales-Corral SA; Tan DX; Acuna-Castroviejo D; Qin L; Yang SF; Xu K
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.